Skip to main content

Advertisement

Table 1 Clinical data parameters used in the model; base-case and sensitivity analysis

From: Cost-effectiveness of posaconazole versusfluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain

Sensitivity analysis
  Base-case estimate Deterministic   Probabilistic  
   Reference   Reference Distribution SD
Within first 100 days of prophylaxis  
Probability of an invasive fungal infection (IFI)  
Posaconazole 0.05 Cornely[10] 0.0344 -0.0573 Assumption Beta 0.0120
SAT 0.11 Cornely[10] 0.0825 -0.1375 Assumption Beta 0.0181
Probability of an IFI-related death  
Posaconazole 0.36 Cornely[10] 0.2678 -0.4464 Assumption Beta 0.1247
SAT 0.48 Cornely[10] 0.3636-0.6060 Assumption Beta 0.0857
Probability of death from other causes (non IFI-related)  
Posaconazole 0.16 Cornely[10] 0.1185-0.1975 Assumption Beta 0.0148
SAT 0.16 Cornely[10] 0.1185-0.1975 Assumption Beta 0.0148
After first 100 days of prophylaxis  
Relative survival associated with acute myelogenous leukaemia (AML)  
IFI 0.21 NCI[32] 0.16-0.26 Assumption Gamma 0.000
No IFI 0.21 NCI[32] 0.16-0.26 Assumption Gamma 0.000
Relative survival associated with myelodysplastic syndrome (MDS)  
IFI 0.08 Kantarjian[33] 0.06-0.10 Assumption Gamma 0.000
No IFI 0.08 Kantarjian[33] 0.06-0.10 Assumption Gamma 0.000
  1. SAT standard azole treatment (fluconazole 81% patients or itraconazole 19% patients) SD standard deviation